Traditional feasibility shows where patients should be.
It doesn’t show how they’ll respond.
Patient interest, eligibility friction, treatment history, and self-reported clinical details can change the true size of your reachable population.
This report reveals what Antidote’s Market Feasibility Tests uncovered across several therapeutic areas, including:
- 37% excluded by one BMI requirement
- Only 4% meeting a narrow device-history criterion
- 35% converting, but just 3% qualifying
- One creative generating 67% of all leads
Discover where recruitment assumptions can break down before sites absorb the burden, budgets increase, and enrollment timelines begin to slip.
Get the MFT Findings
